7 results
To evaluate whether dGEMRIC is suitable as outcome measure to detect changes over time, and also between intervention groups in patients with OA of the knee.
Primary:To describe in a pragmatic setting whether there is an improvement in asthma control from the beginning to the end of the study,when directly switched to mepolizumab, in subjects with a severe eosinophilic asthma phenotype not optimally…
Primary objective of this study is to assess the safety and tolerability, feasibility and biological activity (immunogenicity) of the actively personalized vaccination (APVAC) concept in newly diagnosed glioblastoma (GB) patients.Secondary study…
Primary objective: To evaluate the efficacy of mepolizumab SC given every 4 weeks in participants aged 6 to 17 years with HESSecondary objectives:- To assess the effect of mepolizumab SC given every 4 weeks on the change in oral corticosteroid (OCS…
Primary:To assess the use of mepolizumab in safety syringe for the subcutaneous self-administration of mepolizumab by subjects with severe eosinophilic asthma.Secondary:To assess the use of mepolizumab in safety syringe outside the clinic setting.…
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatory eosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-head comparison of the presence…
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatoryeosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-headcomparison of the presence of…